TABLE 1.
Characteristics of patients included in the analysis (n = 166)
| Variablea | Value for the variableb | IQRc | Ranged |
|---|---|---|---|
| Patients from the Lyon site (% of total) | 71.7 | ||
| Age (yr) | 65 | 53–74 | 19–85 |
| Male patients (% of total) | 65 | ||
| TBW (kg) | 76.5 | 65.2–88.5 | 41.5–137.5 |
| Height (cm) | 170 | 164–175 | 137–190 |
| BSA (m2) | 1.92 | 1.77–2.10 | 1.33–2.63 |
| BMI (kg/m2) | 25.6 | 22.8–29.7 | 16–46 |
| SAPSII score | 48 | 34–63 | 13–100 |
| SOFA score | 5 | 3–8 | 0–16 |
| Patients with a SOFA score of ≥2 (% of total) | 87.3 | ||
| Dose (mg) | 1,985 | 1,500–2,000 | 860–3,000 |
| Dose/TBW (mg/kg) | 23.4 | 20.0–27.0 | 11.0–39.7 |
| Cmax (mg/liter) | 67.2 | 50.1–84.5 | 20.9–139.7 |
| Cmax distribution (% of patients) | |||
| ≥64 mg/liter | 53 | ||
| ≥80 mg/liter | 30 | ||
| Cmin (mg/liter) | 2.7 | 0.4–9.5 | ≤0.3–53.5 |
| Serum creatinine (μmol/liter) | 83 | 59–117 | 23–480 |
| CLCG (ml/min) | 79.8 | 53.2–124.5 | 11.2–300.1 |
| GFR estimated with CKD-EPI (ml/min/1.73m2) | 83.6 | 49.0–103.8 | 9.6–167.0 |
| GFR estimated with MDRD (ml/min/1.73 m2) | 77.6 | 49.0–110.6 | 9.2–300.8 |
| Alanine amino transferase (UI/liter) | 43 | 29–76 | 8–7,272 |
| Aspartate amino transferase (UI/liter) | 31 | 16–64 | 3–3,263 |
a
TBW, total body weight; BSA, body surface area; BMI, body mass index; Cmax, amikacin concentration measured 1 h after start of infusion; Cmin, amikacin concentration measured before the second planned administration; SOFA, sepsis-related organ failure assessment; SAPSII, simplified acute physiology score II; CLCG, creatinine clearance estimated by the original Cockcroft-Gault equation; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
b
Median values are given unless otherwise indicated.
c
IQR, interquartile range.
d
Minimum and maximum values are given.